Skip Navigation



Rheumatology Advance Access published online on April 12, 2005
Rheumatology, doi:10.1093/rheumatology/keh643
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/7/925    most recent
keh643v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Szegedi, A.
Right arrow Articles by Kiss, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szegedi, A.
Right arrow Articles by Kiss, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received January 5, 2005
Accepted March 8, 2005

Original Papers

Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus

A. Szegedi 1*, E. Simics 1, M. Aleksza 2, I. Horkay 1, K. Gaál 1, S. Sipka 2, J. Hunyadi 1, and E. Kiss 2

1 Department of Dermatology, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
2 Third Department of Internal Medicine, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary

* To whom correspondence should be addressed.
A. Szegedi, E-mail: aszegedi{at}jaguar.dote.hu


  Abstract

Objective. Ultraviolet-A1 (UVA1) phototherapy is effective for a variety of dermatological diseases. We examined the effectiveness and reliability of low-dose UVA1 phototherapy (60 kJ/m2/treatment) in patients suffering from systemic lupus erythematosus (SLE). We studied the changes in immunological parameters.

Methods. The patients received a 9-week course of phototherapy according to the following regimen: five times a week during the first 3 weeks, three times a week during the second 3 weeks and twice during the last 3 weeks. Among other things, we analysed the proportions of T helper 1 (Th1), Th2, T cytotoxic (Tc1) and Tc2 cell populations in the peripheral blood of patients by flow cytometric detection of intracytoplasmic interferon {gamma} (IFN-{gamma}) and interleukin 4 (IL-4).

Results. Our study showed the improvement of clinical symptoms determined by the subjective clinical disease activity scoring and the SLE Disease Activity Index (SLEDAI). By the end of UVA1 phototherapy, the mean value of SLEDAI had decreased from 7.2±5.6 to 0.9±1.8, which was significant (P = 0.005). Immunological investigations detected a decrease in the frequency of IFN-{gamma}-producing Th1 and Tc1 cells and a decrease in the Th1/Th2 and Tc1/Tc2 ratios after UVA1 therapy.

Conclusion. According to the literature, IFN-{gamma} has a pathogenic role in the development of SLE. We observed a decreased proportion of IFN-{gamma}-secreting cells, which we think is presumably one of the beneficial effects of UVA1 therapy. On the basis of our study, UVA1 phototherapy does seem to be an effective adjuvant in the treatment of SLE patients.

Keywords: Phototherapy; Systemic lupus erythematosus; Th1; Th2; IFN-{gamma}.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. Pavel
Light therapy (with UVA-1) for SLE patients: is it a good or bad idea?
Rheumatology, June 1, 2006; 45(6): 653 - 655.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.